{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-030870","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2025-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.421875+00:00","generated_at":"2026-05-23T23:49:43.623090+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Edgewise Therapeutics prices $200M common stock offering at $20.13 per share","bullets":["9,935,419 shares priced at $20.13; gross proceeds ~$200M before discounts and expenses.","Closing expected April 3, 2025; anticipated cash runway through 2028 (including existing cash).","Proceeds to fund sevasemten for Becker/Duchenne MD, EDG-7500 HCM trials, and R&D.","Participants include Braidwell, Cormorant, Driehaus, Invus, Janus, MPM, OrbiMed, Paradigm, Perceptive, RA Capital, Sofinnova.","Underwritten by Leerink, Piper Sandler, Guggenheim, and Truist Securities."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-030870","json":"https://secwatch.observer/filing/0001104659-25-030870.json","markdown":"https://secwatch.observer/filing/0001104659-25-030870.md","text":"https://secwatch.observer/filing/0001104659-25-030870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925030870/0001104659-25-030870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925030870/tm2510984d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T23:49:43.623090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}